Chemotherapy resistance in ovarian cancer : New molecular perspectives

Obstetrics and Gynecology

Volumn 91, Issue 5, 1998, Pages 783-792

  Coukos, George ^a   Rubin, Stephen C ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; PROTEIN P53;

APOPTOSIS; DATA BASE; DRUG MECHANISM; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICAL INFORMATION; MEDICAL RESEARCH; MOLECULAR DYNAMICS; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, P53; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0031970615     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1016/S0029-7844(98)00054-4     Document Type: Review

References (116)

1. Wingo P, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Ozols RF, Rubin SC, Thomas G, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: Lippincott-Raven, 1997:919-987.
3. Stewart LA, Guthrie D, Parmar MK, Williams CJ. Chemotherapy in advanced ovarian cancer. BMJ 1992;304:119.
4. Morgan MA, Rubin SC. Secondary cytoreduction in epithelial ovarian cancer. Crit Rev Oncol Hematol 1995;18:1-8.
5. Ringborg U, Platz A. Chemotherapy resistance mechanisms. Acta Oncol 1996;35(Suppl 5):76-80.
6. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996;32:921-926.
7. Fearon ER, Vogelstein B. Tumor suppressor and DNA repair gene defects in human cancer. In: Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weicshelbaum RR, eds. Cancer medicine. Baltimore: Williams and Wilkins, 1997:97-117.
8. Ruley HE. p53 and response to chemotherapy and radiotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and practice of oncology updates. Philadelphia: Lippincott-Raven, 1997;11:1-19.
9. Roth JA. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
10. Rosenberg B, VanCamp L, Grimley EB, Thompson AJ. The inhibition of cell growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem 1964;242:1347-1352.
11. Bellon SF, Coleman JH, Lippard SJ. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cisdiamminedichloroplatinum( II). Biochemistry 1991;30:8026-8035.
12. Chu G. Cellular responses to cisplatin; the roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-790.
13. Heesbeen EC, van Vugt M, Schornagel JH. Cisplatin and carboplatin: Mechanism of drug uptake and potentiation of activity. Annu Rep Natl Cancer Inst 1993:80-81.
14. Mann SC, Andrews PA, Howell SB. Short-term cisdiamminedichloroplatinum( II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 1990;25:236-240.
15. Voeltzel T, Lavaissiere L, Ghilani P, Benard J, Bohuon C, Bidart JM. Detection of a 45-kilodalton antigen overexpressed in a cisplatin-resistant human ovarian carcinoma cell line. Hybridoma 1994;13:367-372.
16. Johnson WS, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer 1993;71:644-649.
17. Chen G, Zeller WJ. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line. J Cancer Res Clin Oncol 1990;116:443-447.
18. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, et al. Augmentation of adriamycin, melphalan, and cisplatin toxicity in drug-resistant and-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985;34:2583-2586.
19. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ, Hamilton TC. Evidence for altered regulation of gammaglutamylcysteine synthetase gene expression among cisplatinsensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 1995;55:4367-4374.
20. Masuda H, Tanaka T, Matsuda H, Kusaba I. Increased removal of DNA-bound platinum in a human ovarian cancer line resistant to cis-diamminedichloroplatinum(II). Cancer Res 1990;50:1863-1866.
21. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, Rossi J. Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients. Anticancer Res 1989;9:1301-1312.
22. Scanlon KJ, Kashani-Sabet M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci USA 1988;85:650-653.
23. Bissett D, McLaughlin K, Kelland LR, Brown R. Cisplatin-DNA damage recognition proteins in human tumour extracts. Br J Cancer 1993;67:742-748.
24. Katz EJ, Andrews PA, Howell SB. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun 1990;2:159-164.
25. Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 1993;20:16-25.
26. Schiff P, Fant J, Horwitz S. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667.
27. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-374.
28. Parker RJ, Daholkar MD, Lee KB, Bostick-Bruton F, Reed E. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Mon 1993;15: 83-88.
29. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-1753.
30. Patel NH, Rothenberg ML. Multidrug resistance and chemotherapy. Invest New Drugs 1994;12:1-13.
31. van der Zee AGJ, Holleman HH, de Bruijn HWA, Willemse PHB, Boonstra H, Mulder N, et al. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 1995;58:165-178.
32. Nasmyth K. Putting the cell cycle in order. Science 1996;274: 1643-1645.
33. Nevins JR. Transcriptional regulation. A closer look at E2F. Nature 1992;358:375-376.
34. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 1992;17:312-315.
35. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
36. Stillman B. Cell cycle control of DNA replication. Science 1996; 274:1659-1664.
37. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, et al. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 1994;5:1301-1307.
38. Hartwell LH, Weinert TA. Checkpoints; controls that ensure the order of cell cycle events. Science 1989;246:629-634.
39. Lane DP. p53, guardian of the genome. Nature 1992;358:15-16.
40. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Trent JM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
41. Yang Z-Y, Perkins ND, Ohno T, Nabel E, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1995;10:1052-1056.
42. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
43. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034-1036.
44. Vaux DL. Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 1993;90:786-791.
45. Martin SJ, Green DR, Cotter TG. Dicing with death: Dissecting the components of the apoptosis machinery. Trends Biochem Sci 1994;19:26-32.
46. Kastan MB, Canman CE, Leonard CL. p53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev 1995; 14:3-15.
47. Nunez G, Clarke MF. The Bcl-2 family of proteins: Regulators of cell death and survival. Trends Cell Biol 1994;4:399-403.
48. Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 1995;85:1007-1010.
49. Kastan MB. p53: Evolutionally conserved and constantly evolving. J Natl Inst Health Res 1993;5:53-57.
50. Sekiguchi I, Suzuki M, Tamada T, Shinomiya N, Tsuru S, Murata M. Effects of cisplatin on cell cycle kinetics, morphological change, and cleavage pattern of DNA in two human ovarian carcinoma cell lines. Oncology 1996;53:19-26.
51. Boyd J, Rubin SC. Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecol Oncol 1997;64:196-206.
52. Rubin SC, Benjamin I, Behbahkt K, Takahashi H, Morgan MA, Livolsi VA, et al. Clinical and pathologic features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-1416.
53. Buller RE, Skilling JS, Kaliszewski S, Niemann T, Anderson B. Absence of significant germ line p53 mutations in ovarian cancer patients. Gynecol Oncol 1995;58:368-374.
54. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-1519.
55. McManus DT, Yap EP, Maxwell P, Russell SE, Toner PG, McGee JO. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994;174:159-168.
56. Hachiya M, Chumakov A, Miller CW, Akashi M, Said J, Koeffler HP. Mutant p53 proteins behave in a dominant negative fashion in vivo. Anticancer Res 1994;14:1853-1859.
57. Milner J. Forms and functions of p53. Semin Cancer Biol 1994;5: 211-219.
58. Hall PA, Lane DP. p53 in tumour pathology-can we trust immunohistochemistry-revisited. J Pathol 1994;172:1-4.
59. Frank TS, Bartos RE, Haefner HK, Roberts JA, Wilson MD, Hubbell GP. Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma. Mod Pathol 1994;7:3-8.
60. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-4965.
61. Righetti SC, Della Torre G, Pillotti S, Menard S, Ottone F, Colnaghi MI, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-694.
62. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993;24:1175-1179.
63. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, et al. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992;84:1793-1798.
64. Zheng J, Benedict WF, Xu HJ, Hu SX, Kim TM, Velicescu M, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 1995;87:1146-1153.
65. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643-650.
66. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26:387-392.
67. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-2132.
68. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-3108.
69. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 1995;64:434-440.
70. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-236.
71. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-234.
72. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994;102:671-676.
73. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-1551.
74. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995;72: 1324-1329.
75. Eastman A. Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cell 1990;2:275-280.
76. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-4626.
77. El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9:79-87.
78. Müller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16: 3845-3848.
79. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997;94:2345-2349.
80. Smith ML, Kontny HU, Bortnick R, Fornace AJ Jr. The p53- regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res 1997;230:61-68.
81. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-3459.
82. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu A. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994;84:3105-3112.
83. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-3157.
84. Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, Crowther D. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: Correlation with histopathology and clinical features. Br J Cancer 1994;69:609-612.
85. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-69.
86. Henriksen R, Strang P, Wilander E, Backstrom, Tribukati B, Oberg K. p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathologic parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-306.
87. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Diamandis EP. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-1338.
88. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-4199.
89. Skilling JS, Squartrito RC, Connor JP, Niemann T, Buller RE. P53 gene mutation analysis and anti-sense mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol Oncol 1996;60:72-80.
90. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviralmediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996;12:1617-1623.
91. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-562.
92. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996;50:1536-1540.
93. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 1995;11:1217-1228.
94. Allday MJ, Inman GJ, Crawford DH, Farrell PJ. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J 1995;14:4994-5005.
95. Zaffaroni N, Benini E, Gornati D, Bearzatto A, Silvestrini R. Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells 1995;13: 77-85.
96. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-684.
97. Vikhanskaya F, D'Incalci M, Broggini M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer 1995;61: 397-401.
98. Isonishi S, Andrews PA, Howell SB. Increase sensitivity to cis-diamminedichloroplatinum in human ovarian carcinoma cells in response to treatment with 12-0-tetradecanoyrphorbol 13- acetate. J Biol Chem 1990;265:3623-3627.
99. Basu A, Weixel KM. Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and-resistant ovarian carcinoma cells. Int J Cancer 1995;62:457-460.
100. Clark S, McGuckin MA, Hurst T, Ward BG. Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines. Cancer Immunol Immunother 1994;39:100-104.
101. Benchekroun MN, Parker R, Dabholkar M, Reed E, Sinha BK. Effects of interleukin-1 alpha on DNA repair in human ovarian carcinoma (NIH:OVCAR-3) cells: Implications in the mechanism of sensitization of cis-diamminedichloroplatinum(II). Mol Pharmacol 1995;47:1255-1260.
102. Barnes MN, Deshane JS, Rosenfeld M, Siegal GP, Curiel DT, Alvarez RD. Gene therapy and ovarian cancer: A review. Obstet Gynecol 1997;89:145-155.
103. Guttierez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992;339:715-721.
104. Runnebaum IB, Kreienberg R. p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: An expeditious in vitro protocol with implications towards gene therapy. Hybridoma 1995;14:153-157.
105. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirusmediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55:4210-4213.
106. Liu T-J, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995;55:3117-3122.
107. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Gregory RJ, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996;3:121-130.
108. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995;6:395-405.
109. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55:5151-5155.
110. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mishak RP, et al. A monoclonal antibody against c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51: 4575-4580.
111. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC. Liposomemediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 1995; 11:1383-1388.
112. Deshane J, Siegal GP, Wang M, Wright M, Bucy RP, Alvarez RD, et al. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single chain antibody for ovarian cancer gene therapy. Gynecol Oncol 1997;64:378-385.
113. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-991.
114. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996;23:66-77.
115. Katso RMT, Manek S, O'Byrne K, Playford MP, Le Meuth V, Ganesan TS. Molecular approaches to diagnosis and management of ovarian cancer. Cancer Metastasis Rev 1997;16:81-107.
116. Berchuck A, Bast RC Jr. p53-based gene therapy of ovarian cancer: Magic bullet? Gynecol Oncol 1995;59:169-170.